However, since tumor markers in addition to CD133 have been identified in GSCs (Lathia et al., 2015), studies on purine metabolism alterations should be carried out also in other GSC types and related intracranial xenograft animal models to assess the existence of MTAP loss or further/different purine metabolism dysregulation in them. This evidence concerns the gene MTAP and neoplasm.